Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
26.79
-2.43 (-8.33%)
At close: Nov 16, 2026, 4:00 PM EST
26.78
0.00 (-0.02%)
After-hours: Nov 16, 2026, 4:04 PM EST
Viking Therapeutics Stock Forecast
Stock Price Forecast
According to 21 analysts polled by S&P Global, Viking Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $95.32. The average 1-year stock price forecast is 255.87% higher than the current stock price, while the lowest is $34 (+26.94%) and the highest is $125 (+366.68%).
Price Target: $95.32 (+255.87%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Viking Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 13 | 13 | 13 | 14 | 14 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 20 | 20 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Reiterates $95 | Buy | Reiterates | $95 | +254.68% | Nov 16, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $102 | Buy | Reiterates | $102 | +280.81% | Nov 16, 2026 |
| Maxim Group | Maxim Group | Buy Reiterates $70 | Buy | Reiterates | $70 | +161.34% | Oct 30, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $106 → $118 | Buy | Maintains | $106 → $118 | +340.55% | Oct 30, 2026 |
| B. Riley Securities | B. Riley Securities | Buy Maintains $85 | Buy | Maintains | $85 | +217.34% | Oct 29, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-5.31
from -3.19
EPS Next Year
-5.21
from -5.31
EPS and Forward PE are based on non-GAAP adjusted numbers.